저자 : Fudan University Shanghai Cancer Center, Shanghai Medical College, Department of Medical Oncology, Shanghai, China
출처 : EXPERT OPINION
Abstract
Introduction: Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib mesylate, a small molecule tyrosine kinase inhibitor targeting
vascular endothelial growth factor receptor-2, has been recommended as third-line treatment for metastatic gastric cancer patients.
Areas covered: The current review summarizes the publications and conference reports relating to apatinib from preclinical and clinical research in gastric cancer.
Apatinib showed good safety, tolerance and treatment efficacy in Phase I/II studies. In a Phase III study, apatinib prolonged the median overall survival of patients with chemotherapy-refractory metastatic gastric cancer by 55 days and the median progression-free survival by 25 days compared with placebo.
Expert opinion: Apatinib is a new treatment option for advanced gastric cancer.
Apatinib is expected to have a broader application when it has been evaluated worldwide.
The key issues are to find biomarkers and overcome drug resistance.